Literature DB >> 23143542

Amelioration of hyperoxia-induced lung injury using a sphingolipid-based intervention.

Jeroen Tibboel1, Stephen Joza, Irwin Reiss, Johan C de Jongste, Martin Post.   

Abstract

The aim of this study was to characterise lung function and bronchoalveolar lavage sphingolipid profile in newborn mice during hyperoxia exposure and recovery in room air, and to examine the effect of d-sphingosine supplementation during recovery. Newborn mice were exposed to 80% oxygen for 4 weeks and allowed to recover in room air for another 4 weeks. Lung function measurements and morphometrical analysis of lung tissue were performed and bronchoalveolar lavage fluid was collected during hyperoxia and recovery with and without d-sphingosine supplementation. Hyperoxia exposure altered lung function, which partially recovered in room air. Lungs had fewer and enlarged alveoli which persisted during recovery. Multiple sphingolipids were significantly increased after hyperoxia. Ceramides were increased after 2 weeks of recovery, but normalised to control values after 4 weeks. The addition of d-sphingosine during the first 5 days of recovery accelerated the normalisation of ceramide levels at 2 weeks and partially reversed the hyperoxia-induced increase in alveolar size and arrest in alveolarisation at 4 weeks. Exposure of newborn mice to hyperoxia caused restrictive and obstructive lung function changes that partially recovered in room air, while alveolar morphology remained abnormal. Hyperoxia increased ceramide levels, with normalisation after recovery. d-sphingosine addition during recovery reduced ceramide levels and ameliorated hyperoxia-induced alveolar arrest.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143542     DOI: 10.1183/09031936.00092212

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

1.  Fatty Acid Oxidation Protects against Hyperoxia-induced Endothelial Cell Apoptosis and Lung Injury in Neonatal Mice.

Authors:  Hongwei Yao; Jiannan Gong; Abigail L Peterson; Xuexin Lu; Peng Zhang; Phyllis A Dennery
Journal:  Am J Respir Cell Mol Biol       Date:  2019-06       Impact factor: 6.914

Review 2.  Advancements in understanding the role of lysophospholipids and their receptors in lung disorders including bronchopulmonary dysplasia.

Authors:  Tara Sudhadevi; Alison W Ha; David L Ebenezer; Panfeng Fu; Vijay Putherickal; Viswanathan Natarajan; Anantha Harijith
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-03-10       Impact factor: 4.698

Review 3.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

Review 4.  Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia.

Authors:  Vineet Bhandari
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-02-27

5.  Neonatal therapy with PF543, a sphingosine kinase 1 inhibitor, ameliorates hyperoxia-induced airway remodeling in a murine model of bronchopulmonary dysplasia.

Authors:  Alison W Ha; Tara Sudhadevi; David L Ebenezer; Panfeng Fu; Evgeny V Berdyshev; Steven J Ackerman; Viswanathan Natarajan; Anantha Harijith
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-07-22       Impact factor: 5.464

Review 6.  Animal models of bronchopulmonary dysplasia. The term mouse models.

Authors:  Jessica Berger; Vineet Bhandari
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-10       Impact factor: 5.464

7.  Prevention of hyperoxia-induced bronchial hyperreactivity by sildenafil and vasoactive intestinal peptide: impact of preserved lung function and structure.

Authors:  Dorottya Czövek; Ferenc Peták; Yves Donati; Xavier Belin; Jean-Claude Pache; Constance Barazzone Argiroffo; Walid Habre
Journal:  Respir Res       Date:  2014-08-13

Review 8.  Sphingolipids as cell fate regulators in lung development and disease.

Authors:  Joyce Lee; Behzad Yeganeh; Leonardo Ermini; Martin Post
Journal:  Apoptosis       Date:  2015-05       Impact factor: 4.677

9.  Ceramides: a potential therapeutic target in pulmonary emphysema.

Authors:  Jeroen Tibboel; Irwin Reiss; Johan C de Jongste; Martin Post
Journal:  Respir Res       Date:  2013-10-01

10.  Intravenous and intratracheal mesenchymal stromal cell injection in a mouse model of pulmonary emphysema.

Authors:  Jeroen Tibboel; Richard Keijzer; Irwin Reiss; Johan C de Jongste; Martin Post
Journal:  COPD       Date:  2013-12-02       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.